B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
15 09 2020
Historique:
pubmed: 3 9 2020
medline: 28 10 2020
entrez: 3 9 2020
Statut: ppublish

Résumé

Animal models of human antigen-specific B cell receptors (BCRs) generally depend on "inferred germline" sequences, and thus their relationship to authentic naive human B cell BCR sequences and affinities is unclear. Here, BCR sequences from authentic naive human VRC01-class B cells from healthy human donors were selected for the generation of three BCR knockin mice. The BCRs span the physiological range of affinities found in humans, and use three different light chains (VK3-20, VK1-5, and VK1-33) found among subclasses of naive human VRC01-class B cells and HIV broadly neutralizing antibodies (bnAbs). The germline-targeting HIV immunogen eOD-GT8 60mer is currently in clinical trial as a candidate bnAb vaccine priming immunogen. To attempt to model human immune responses to the eOD-GT8 60mer, we tested each authentic naive human VRC01-class BCR mouse model under rare human physiological B cell precursor frequency conditions. B cells with high (HuGL18

Identifiants

pubmed: 32873644
pii: 2004489117
doi: 10.1073/pnas.2004489117
pmc: PMC7502816
doi:

Substances chimiques

AIDS Vaccines 0
Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Broadly Neutralizing Antibodies 0
CD4 Antigens 0
HIV Antibodies 0
HIV Antigens 0
Receptors, Antigen, B-Cell 0
VRC01 monoclonal antibody 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22920-22931

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI073148
Pays : United States
Organisme : NIAID NIH HHS
ID : K99 AI145762
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI125179
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128836
Pays : United States

Informations de copyright

Copyright © 2020 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Competing interest statement: W.R.S. is an inventor on a patent application submitted by IAVI and The Scripps Research Institute that covers the eOD-GT8 immunogen. W.R.S. is involved as a principal investigator of a human clinical trial involving eOD-GT8 60mer (G001). As part of that involvement, W.R.S. is privy to certain clinical trial data, and he was forbidden from sharing that data with the authors of this study during the course of this HuGL study, as is standard for blinded clinical trials. Any conclusions in this manuscript regarding relationships between HuGL mouse models and humans were made by the other authors, without input from W.R.S. related to any clinical trial activities.

Références

J Immunol. 2011 Oct 1;187(7):3785-97
pubmed: 21908739
J Immunol. 2013 Sep 15;191(6):3186-3191
pubmed: 23940276
PLoS Pathog. 2016 Aug 25;12(8):e1005815
pubmed: 27560183
Cell Rep. 2019 Dec 3;29(10):3060-3072.e7
pubmed: 31801073
Science. 2019 Dec 6;366(6470):
pubmed: 31806786
Immunol Rev. 2017 Jan;275(1):49-61
pubmed: 28133798
Science. 2019 Dec 6;366(6470):
pubmed: 31672916
Science. 2010 Aug 13;329(5993):811-7
pubmed: 20616231
J Exp Med. 2018 Oct 1;215(10):2686-2695
pubmed: 30181412
Curr Opin Immunol. 2018 Aug;53:209-216
pubmed: 30190230
Cell. 2016 Sep 8;166(6):1471-1484.e18
pubmed: 27610571
Science. 2016 Mar 25;351(6280):1458-63
pubmed: 27013733
Science. 2013 May 10;340(6133):711-6
pubmed: 23539181
J Exp Med. 2017 Sep 4;214(9):2573-2590
pubmed: 28847869
Curr Opin Immunol. 2017 Apr;45:21-30
pubmed: 28088708
Cell. 2015 Jun 18;161(7):1505-15
pubmed: 26091035
Science. 2016 Sep 30;353(6307):1557-1560
pubmed: 27608668
Curr Opin Immunol. 2016 Apr;39:59-67
pubmed: 26799208
Sci Transl Med. 2018 May 16;10(441):
pubmed: 29769285
Nature. 2019 Jun;570(7762):468-473
pubmed: 31142836
Cell. 2016 Sep 8;166(6):1459-1470.e11
pubmed: 27610570
PLoS Pathog. 2019 Sep 17;15(9):e1008026
pubmed: 31527908
Annu Rev Immunol. 2017 Apr 26;35:255-284
pubmed: 28142324
Sci Transl Med. 2018 Jul 4;10(448):
pubmed: 29973404
Nat Immunol. 2017 Apr;18(4):456-463
pubmed: 28192417
Annu Rev Immunol. 2012;30:429-57
pubmed: 22224772
Immunity. 2018 Aug 21;49(2):301-311.e5
pubmed: 30076101
Cell. 2018 Jun 14;173(7):1783-1795.e14
pubmed: 29731169
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4743-4748
pubmed: 29666227
PLoS Pathog. 2013;9(5):e1003342
pubmed: 23658524
Immunity. 2016 Nov 15;45(5):1108-1121
pubmed: 27851912
Retrovirology. 2018 Sep 5;15(1):61
pubmed: 30185183
J Immunol. 2013 Sep 15;191(6):3179-85
pubmed: 23940273
Cell. 2019 Apr 18;177(3):524-540
pubmed: 31002794
Cell. 2015 Oct 22;163(3):545-8
pubmed: 26496601
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
Immunity. 2016 Sep 20;45(3):483-496
pubmed: 27617678
Immunity. 2018 May 15;48(5):855-871
pubmed: 29768174
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):E3268-77
pubmed: 23115339
Immunity. 2018 Dec 18;49(6):1162-1174.e8
pubmed: 30552024
Immunity. 2016 Mar 15;44(3):542-552
pubmed: 26948373
J Exp Med. 2013 Apr 8;210(4):655-63
pubmed: 23530120
Immunity. 2013 Aug 22;39(2):245-58
pubmed: 23911655
Immunity. 2019 Oct 15;51(4):735-749.e8
pubmed: 31563464
Science. 2015 Jul 10;349(6244):156-61
pubmed: 26089355
Immunology. 2017 Dec;152(4):602-612
pubmed: 28746783
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Immunity. 2016 Apr 19;44(4):939-50
pubmed: 27067056
Nat Commun. 2016 Feb 24;7:10618
pubmed: 26907590
Cell. 2016 Sep 8;166(6):1445-1458.e12
pubmed: 27610569
EMBO J. 2018 Sep 14;37(18):
pubmed: 30087111
J Exp Med. 2016 Apr 4;213(4):469-81
pubmed: 27022144
Cold Spring Harb Perspect Biol. 2017 Nov 1;9(11):
pubmed: 28159875
Trends Immunol. 2018 Jul;39(7):549-561
pubmed: 29789196
Cold Spring Harb Perspect Biol. 2018 May 1;10(5):
pubmed: 28630079
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Nature. 2019 Nov;575(7781):119-129
pubmed: 31695203
Immunity. 2019 Jul 16;51(1):141-154.e6
pubmed: 31315032
J Immunol. 2013 Sep 1;191(5):2538-50
pubmed: 23918977

Auteurs

Deli Huang (D)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Robert K Abbott (RK)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.

Colin Havenar-Daughton (C)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.

Patrick D Skog (PD)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Rita Al-Kolla (R)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037.

Bettina Groschel (B)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.

Tanya R Blane (TR)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Sergey Menis (S)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.

Jenny Tuyet Tran (JT)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Theresa C Thinnes (TC)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Sabrina A Volpi (SA)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Alessia Liguori (A)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.

Torben Schiffner (T)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.

Sophia M Villegas (SM)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.

Oleksandr Kalyuzhniy (O)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.

Mark Pintea (M)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

James E Voss (JE)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Nicole Phelps (N)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.

Ryan Tingle (R)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.

Alberto R Rodriguez (AR)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Greg Martin (G)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Sergey Kupryianov (S)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Allan deCamp (A)

Vaccine and Infectious Disease Division, Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.

William R Schief (WR)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139.

David Nemazee (D)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037; nemazee@scripps.edu shane@lji.org.

Shane Crotty (S)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037; nemazee@scripps.edu shane@lji.org.
Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92037.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH